Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share

DYADIC INTERNATIONAL INC

2026-Q1 EPS reported -$0.05 vs consensus -$0.04 ▼ miss (-22.5%)

Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.
Cash and investments $6.6M as of March 31, 2026, down from $8.6M at Dec 31, 2025.
Received initial purchase orders for recombinant bovine transferrin from cultivated meat customers.
Proliant Health launched AlbuFree™ DX, with Dyadic entitled to profit share; expanded Fermbox Bio collaboration.
Signed OEM distribution agreement with IBT Bioservices; advanced Gates Foundation RSV/malaria and CEPI/FBS H5 programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DYADIC INTERNATIONAL INC reported financial results for Q1 2026.

Period: Q1 2026
Result: reported results

Exact text from the filing

Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2026.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001493152-26-022727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.